Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G D MacLean

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|March 1, 1987
Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancersB M Longenecker, D J Willans, G D MacLean, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivoC M Henningsson, S Selvaraj, G D MacLean, et al.
International Journal of Cancer|May 16, 1995
CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapyM B Yacyshyn, S Poppema, A Berg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccineB M Sandmaier, D V Oparin, L A Holmberg, et al.
International Journal of Cancer|June 17, 1998
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptideM Reddish, G D MacLean, R R Koganty, et al.
The International Journal of Biological Markers|April 1, 1991
Clinical evaluation of a new two-site assay for CA125 antigenV Capstick, G D Maclean, M R Suresh, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantG D MacLean, M Reddish, R R Koganty, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 19, 2000
The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patientsS A McQuarrie, T Riauka, R P Baum, et al.
Gynecologic Oncology|July 1, 1995
Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervixR G Pearcey, G C Stuart, G D MacLean, et al.
The International Journal of Biological Markers|January 1, 1991
Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer managementJ L Jensen, G D Maclean, M R Suresh, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|March 1, 1987
Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancersB M Longenecker, D J Willans, G D MacLean, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivoC M Henningsson, S Selvaraj, G D MacLean, et al.
International Journal of Cancer|May 16, 1995
CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapyM B Yacyshyn, S Poppema, A Berg, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccineB M Sandmaier, D V Oparin, L A Holmberg, et al.
International Journal of Cancer|June 17, 1998
Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptideM Reddish, G D MacLean, R R Koganty, et al.
The International Journal of Biological Markers|April 1, 1991
Clinical evaluation of a new two-site assay for CA125 antigenV Capstick, G D Maclean, M R Suresh, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantG D MacLean, M Reddish, R R Koganty, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 19, 2000
The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patientsS A McQuarrie, T Riauka, R P Baum, et al.
Gynecologic Oncology|July 1, 1995
Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervixR G Pearcey, G C Stuart, G D MacLean, et al.
The International Journal of Biological Markers|January 1, 1991
Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer managementJ L Jensen, G D Maclean, M R Suresh, et al.
Pageof 4